HOUSTON, Sept. 16, 2019 /PRNewswire/ -- Moleculin
Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a
clinical stage pharmaceutical company with a broad portfolio of
drug candidates targeting highly resistant tumors, today announced
its sponsored research at MD Anderson Cancer Center has resulted in
the filing of a new patent on behalf of MD Anderson Cancer Center
covering the combination of its
immune-stimulating/transcriptional-modulator, WP1066, with
well-known immune checkpoint inhibitors.
"We had previously announced preliminary preclinical data
showing beneficial therapeutic effect from WP1066 when used in
combination with PDL-1 and CTLA-4 immune checkpoint inhibitors in
pancreatic cancer models," commented Walter
Klemp, Moleculin's Chairman and CEO. "We are pleased
to report the filing of a patent on behalf of MD Anderson Cancer
Center for this new discovery that opens new potentially effective
approaches to utilize check point inhibitors for treatment of
pancreatic cancer and other types cancers that are unresponsive to
current immunotherapies. These studies were supported by our
sponsored research agreement with MD Anderson Cancer Center.
Pursuant to the terms of our Sponsored Research Agreement, we
intend to add this to our already diverse list of technology
licenses."
About Moleculin Biotech, Inc.
Moleculin Biotech, Inc. is a clinical stage pharmaceutical
company focused on the development of a broad portfolio of oncology
drug candidates for the treatment of highly resistant tumors. The
Company's clinical stage drugs are: Annamycin, a Next Generation
Anthracycline, designed to avoid multidrug resistance mechanisms
with little to no cardiotoxicity being studied for the treatment of
relapsed or refractory acute myeloid leukemia, more commonly
referred to as AML, WP1066, an Immune/Transcription Modulator
capable of inhibiting p-STAT3 and other oncogenic transcription
factors while also stimulating a natural immune response, targeting
brain tumors, pancreatic cancer and hematologic malignancies, and
WP1220, an analog to WP1066, for the topical treatment of cutaneous
T-cell lymphoma. Moleculin is also engaged in preclinical
development of additional drug candidates, including additional
Immune/Transcription Modulators, as well as compounds capable of
Metabolism/Glycosylation Inhibition.
For more information about the Company, please visit
http://www.moleculin.com.
Forward-Looking Statements
Some of the statements in this release are forward-looking
statements within the meaning of Section 27A of the Securities Act
of 1933, Section 21E of the Securities Exchange Act of 1934 and the
Private Securities Litigation Reform Act of 1995, which involve
risks and uncertainties. Forward-looking statements in this press
release include, without limitation, the ability of parties acting
on behalf of MD Anderson Cancer Center to successfully prosecute
the patent application and the ability of WP1066 to show safety and
efficacy in combination with immune checkpoint inhibitors in
humans. Although Moleculin believes that the expectations reflected
in such forward-looking statements are reasonable as of the date
made, expectations may prove to have been materially different from
the results expressed or implied by such forward-looking
statements. Moleculin Biotech has attempted to identify
forward-looking statements by terminology including ''believes,''
''estimates,'' ''anticipates,'' ''expects,'' ''plans,''
''projects,'' ''intends,'' ''potential,'' ''may,'' ''could,''
''might,'' ''will,'' ''should,'' ''approximately'' or other words
that convey uncertainty of future events or outcomes to identify
these forward-looking statements. These statements are only
predictions and involve known and unknown risks, uncertainties, and
other factors, including those discussed under Item 1A. "Risk
Factors" in our most recently filed Form 10-K filed with the
Securities and Exchange Commission ("SEC") and updated from time to
time in our Form 10-Q filings and in our other public filings with
the SEC. Any forward-looking statements contained in this
release speak only as of its date. We undertake no obligation to
update any forward-looking statements contained in this release to
reflect events or circumstances occurring after its date or to
reflect the occurrence of unanticipated events. The Company
cautions investors not to place undue reliance on the interim
results announced today.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/moleculin-announces-its-sponsored-research-at-md-anderson-cancer-center-has-resulted-in-the-filing-of-patent-protection-for-new-discovery-300918401.html
SOURCE Moleculin Biotech, Inc.